394 related articles for article (PubMed ID: 26044924)
1. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
2. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme.
Smailyte G; Aleknaviciene B
Public Health; 2012 Dec; 126(12):1075-7. PubMed ID: 22381571
[TBL] [Abstract][Full Text] [Related]
3. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
4. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
5. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
7. Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population-Evidence from National PSA-Based Screening Program.
Patasius A; Smailyte G
Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816821
[TBL] [Abstract][Full Text] [Related]
8. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
Jonsson H; Holmström B; Duffy SW; Stattin P
Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
10. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
[TBL] [Abstract][Full Text] [Related]
11. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
12. The Aging Mountaineer: PSA screening in older men--of value or should we skip this test?
Crigger C; Salkini M; Zaslau S
W V Med J; 2016; 112(3):36-40. PubMed ID: 27301153
[TBL] [Abstract][Full Text] [Related]
13. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
Coldman AJ; Phillips N; Pickles TA
CMAJ; 2003 Jan; 168(1):31-5. PubMed ID: 12515782
[TBL] [Abstract][Full Text] [Related]
14. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
15. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
16. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
17. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
18. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer mortality in the Finnish randomized screening trial.
Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
[TBL] [Abstract][Full Text] [Related]
20. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
Li J; Zhao G; Hall IJ
Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]